PLRZ News & Events

Polyrizon announced the publication of U.S. patent application No. US 2024/0358741 A1, titled "Mucoadhesive Polymers for Nasal Drug Delivery". The patent application covers Polyrizon's proprietary Trap & Target mucoadhesive polymer technology platform for nasal drug delivery. The technology is designed to enhance the interaction between pharmaceutical formulations and the nasal mucosa, potentially increasing formulation retention, improving drug absorption, and enabling more efficient delivery of active pharmaceutical ingredients through the nasal route.

Polyrizon announced the signing of its first clinical trial agreement with a U.S.-based clinical research site specializing in allergy studies, marking a milestone toward the initiation of its clinical program for the Nasarix Allergy Blocker. The clinical site, located in Texas, will serve as the first participating center in Polyrizon's planned multi-center study evaluating the safety, tolerability, and efficacy of the Nasarix Allergy Blocker in patients with seasonal allergic rhinitis. The clinical study will assess the performance of Polyrizon's investigational nasal spray designed to create a protective barrier against airborne allergens. The study is planned as a multi-center trial, with additional clinical sites expected to be added in the coming months. The trial will be conducted in accordance with international Good Clinical Practice standards and applicable regulatory requirements, supporting Polyrizon's broader regulatory strategy.